Definium Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $3.65B
- P/E (TTM)
- –
- Dividend yield
- –
About Definium Therapeutics
Medicinal Chemicals & Botanical Products, SIC 2833
Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for brain health disorders. The company's pipeline consists of pharmaceutically optimized product candidates derived from psychedelic and empathogen drug classes. Its lead product candidate, DT120 ODT, is an orally disintegrating tablet formulation of lysergide D-tartrate being evaluated for adult patients with generalized anxiety disorder and major depressive disorder. Its second lead candidate, DT402, is an optimized form of the R-enantiomer of MDMA under evaluation to address core symptoms in adult patients with autism spectrum disorder.
The company operates without internal manufacturing infrastructure, contracting third-party development and manufacturing organizations to produce its clinical supplies under Good Manufacturing Practices. Definium Therapeutics maintains research collaborations, including an exclusive worldwide partnership with a pharmacology research laboratory in Basel, Switzerland, and holds patents and patent applications across regions including the United States, Europe, Canada, and Asia. Definium Therapeutics was incorporated under the laws of the Province of British Columbia, while its wholly-owned subsidiary was incorporated in Delaware.
Summary of the business section of Definium Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Definium Therapeutics, Inc.
- Founded
- 2010
- Headquarters
- New York, NY
- Address
- One World Trade Center, Suite 8500 10007
- Phone
- (212) 220-6633
- Website
- definiumtx.com
- Employees
- 105, Dec 31, 2025
- Industry
- Medicinal Chemicals & Botanical Products
- Incorporated in
- A1
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Diego, California
Stock & identifiers
- Ticker
- DFTX
- Exchange
- Nasdaq
- Shares outstanding
- 134M, Jul 30, 2026
- Public float
- $487.70M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-15 reverse, Nov 10, 2022; 1-for-15 reverse, Aug 29, 2022
- SEC CIK
- 1813814
- CUSIP
- 24477V105
- ISIN
- US24477V1052
- LEI
- 549300QY8KN1O6RPFJ13
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert Barrow | Chief Executive Officer, Director | 2,213,090 |
| Daniel Karlin | Chief Medical Officer, Director | 792,846 |
| Mark Sullivan | Chief Legal Officer | 494,228 |
| Brandi Roberts | Chief Financial Officer | 394,528 |
| Matthew T. Wiley | Chief Commercial Officer | 359,036 |
| Carrie Liao | Chief Accounting Officer | 144,923 |
| Carol A. Vallone | Director | 22,296 |
| Andreas Krebs | Director | 21,402 |
| David W. Gryska | Director | 19,900 |
| Suzanne Louise Bruhn | Director | 24,289 |
| Roger Adsett | Director | 3,555 |
| Roger Crystal | Director | 24,289 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 105 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 12, 2026 | Name change | Name changed from Mind Medicine (MindMed) Inc. to Definium Therapeutics, Inc. |
| Jun 2, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 28, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Apr 22, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |